Autolus Therapeutics (AUTL) Current Leases (2019 - 2025)

Autolus Therapeutics (AUTL) has reported Current Leases for 7 consecutive years, with $4.6 million the latest figure, recorded in Q4 2025.

• Quarterly Current Leases rose 52.27% year-over-year to $4.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $4.6 million (up 52.27% YoY) and the FY2025 annual result came in at $4.6 million, up 52.27% from the prior year.
• Current Leases fell to $4.6 million in Q4 2025 per AUTL's latest filing, from $4.8 million in the prior quarter.
• Over the last five years, Current Leases for AUTL reached as high as $6.2 million in Q2 2023 and fell as low as $3.0 million in Q1 2025.
• A 5-year average of $4.3 million and a median of $4.3 million in 2021 frame the typical range for Current Leases.
• Annual changes were most pronounced in 2023 — Current Leases surged 55.97% — and 2024, when it tumbled 40.67%.
• Year by year, Current Leases stood at $4.5 million in 2021, then rose by 13.14% to $5.0 million in 2022, then rose by 0.3% to $5.1 million in 2023, then slumped by 40.67% to $3.0 million in 2024, then jumped by 52.27% to $4.6 million in 2025.
• According to Business Quant data, Current Leases over the past three periods registered $4.6 million, $4.8 million, and $3.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.